Comparative Pharmacology
Head-to-head clinical analysis: PENAPAR VK versus PENBRITIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PENAPAR VK versus PENBRITIN.
PENAPAR-VK vs PENBRITIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Penicillin V is a bactericidal antibiotic that inhibits cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation, and activating autolytic enzymes.
Penicillin G inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidase activity and preventing peptidoglycan cross-linking, leading to cell lysis.
250-500 mg orally every 6 hours; maximum 2 g/day.
250-500 mg orally every 6 hours; 500 mg to 2 g intramuscularly or intravenously every 4-6 hours.
None Documented
None Documented
Terminal elimination half-life: 0.5–1 hour in normal renal function; prolonged to 7–10 hours in severe renal impairment (anuria). Requires dose adjustment in renal failure.
0.5-1 hour in normal renal function; extended to 2-6 hours in renal impairment. Hemodialysis shortens half-life.
Primarily renal excretion (tubular secretion) of unchanged drug (~90%); minor biliary/fecal elimination (<10%).
Renal: ~75-90% unchanged via glomerular filtration and tubular secretion. Biliary: ~10% in feces. Minor hepatic metabolism to penicilloic acid.
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic